Glaukos Corporation
Moat Score — Glaukos Corporation
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Glaukos holds more than 500 patents and applications protecting the iStent, iDose TR, and iLink platforms, and it effectively created the MIGS device category it still leads. This deep, category-defining IP position is extremely difficult for a new entrant to replicate quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Glaukos is a premium-priced specialty device company, not a low-cost producer; its devices and bio-activated therapies carry high list prices justified by clinical differentiation rather than manufacturing cost leadership. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the creator of novel reimbursed categories (MIGS devices, sustained-release glaucoma implants), Glaukos has meaningful pricing power, though it is bounded by Medicare MAC coverage decisions and Medicaid rebate/340B obligations that cap how far it can push prices. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is no meaningful network effect; procedure volume grows with surgeon training and reimbursement, not because more surgeons using the device makes it inherently more valuable to other surgeons. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Surgeons trained on iStent/iDose techniques and hospitals with established formulary and billing-code workflows face real friction switching to a competing MIGS platform, giving Glaukos a moderate retention advantage once adopted. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The MIGS and bio-activated corneal therapy niches are narrow enough, and R&D/clinical trial costs high enough, that only a handful of players (Alcon, Sight Sciences, New World Medical) can compete at scale, giving incumbents like Glaukos a durable position. |